SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Babjuk M, Burger M, Zigeuner R, et al; European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639-653.
  • 2
    Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7:43-51.
  • 3
    Hunink MG, Glasziou PP, Siegel JE, et al. Decision Making in Health and Medicine: Interpreting Evidence and Values. Cambridge, UK: Cambridge University Press; 2001.
  • 4
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-481.
  • 5
    Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124-1129.
  • 6
    Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med. 2007;4:e284.
  • 7
    Ministere de la Sante et des Services Sociaux. Banque de Donnees APR-DRG 2010-2011 et Contour Financier de Sante Physique (Ministry of Health and Social Services, Database APR-DRG 2010-2011 and financial outline of physical Health). informa.msss.gouv.qc.ca/Details.aspx?Id=OLgRnU5HvPw=. Accessed December 2013.
  • 8
    Regie de l'Assurance Maladie du Quebec. Manuel des Medecins Specialistes. Quebec: Regie de l'Assurance Maladie du Quebec; 2012.
  • 9
    Regie de l'Assurance Maladie du Quebec. Liste de Medicaments Assures. Quebec: Regie de l'Assurance Maladie du Quebec; 2012.
  • 10
    Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York: Oxford University Press; 2005.
  • 11
    Svatek RS, Hollenbeck BK, Holmang S, et al. The economics of bladder cancer: costs and considerations of caring for this disease [published online ahead of print January 21, 2014]. Eur Urol. doi: 10.1016/j.eururo.2014.01.006.
  • 12
    Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518-528.
  • 13
    Bachir BG, Shariat SF, Zlotta A, et al; Bladder Cancer Think Tank (Bladder Cancer Advocacy Network); Canadian Bladder Cancer Network (Bladder Cancer Canada). Demographic analysis of randomized controlled trials in bladder cancer. BJU Int. 2013;111:419-426.
  • 14
    Feifer A, Xie X, Brophy JM, Segal R, Kassouf W. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Urology. 2010;76:652-656.
  • 15
    Lee CT, Barocas D, Globe DR, et al. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. J Urol. 2012;188:2114-2119.
  • 16
    Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol. 2013;64:421-430.
  • 17
    Kassouf W, Kamat AM, Zlotta A, et al. Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. Can Urol Assoc J. 2010;4:168-173.
  • 18
    American Urological Association. Guideline for the management of nonmuscle invasive bladder cancer. auanet.org/education/guidelines/bladder-cancer.cfm. Accessed December 2013.
  • 19
    Barocas DA, Liu A, Burks FN, et al. Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer. J Urol. 2013;190:2011-2016.
  • 20
    Palou-Redorta J, Roupret M, Gallagher JR, Heap K, Corbell C, Schwartz B. The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries. World J Urol. 2014;32:525-530.
  • 21
    Cookson MS, Chang SS, Oefelein MG, Gallagher JR, Schwartz B, Heap K. National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol. 2012;187:1571-1576.
  • 22
    Remak E, Charbonneau C, Negrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3995-4000.
  • 23
    Zhong L, Pon V, Srinivas S, et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PloS One. 2013;8:e64275.
  • 24
    Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control. 2000;7:335-339.
  • 25
    Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology. 2000;14:719-729; discussion 729-731, 734, 737.
  • 26
    Racioppi M, Volpe A, Falabella R, et al. The cost of treatment and follow-up of bladder cancer in Italy. Arch Ital Urol Androl. 2007;79:111-117.